Patents by Inventor Matthew L. Sherman

Matthew L. Sherman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating vascular eye disorders with ActRII antagonists
    Patent number: 11524990
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: December 13, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20220204576
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: August 5, 2021
    Publication date: June 30, 2022
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20220204588
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: August 5, 2021
    Publication date: June 30, 2022
    Inventor: Matthew L. Sherman
  • METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
    Publication number: 20220118049
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
    Type: Application
    Filed: May 27, 2021
    Publication date: April 21, 2022
    Inventors: Matthew L. Sherman, Niels Borgstein
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20210355191
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: December 23, 2020
    Publication date: November 18, 2021
    Inventor: Matthew L. Sherman
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20210355181
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: December 23, 2020
    Publication date: November 18, 2021
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • METHODS FOR TREATING FATTY LIVER DISEASE
    Publication number: 20210269494
    Abstract: In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
    Type: Application
    Filed: October 16, 2020
    Publication date: September 2, 2021
    Inventors: Alan Koncarevic, Jennifer Lachey, Jasbir Seehra, Matthew L. Sherman
  • METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
    Publication number: 20200360475
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb antagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.
    Type: Application
    Filed: January 7, 2020
    Publication date: November 19, 2020
    Inventors: Matthew L. Sherman, Niels Borgenstein
  • ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20200255495
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: September 13, 2019
    Publication date: August 13, 2020
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • METHODS FOR TREATING EYE DISORDERS
    Publication number: 20200071383
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 5, 2020
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • Methods for treating vascular eye disorders with actrii antagonists
    Patent number: 10550170
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 4, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20200031903
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: January 4, 2019
    Publication date: January 30, 2020
    Inventor: Matthew L. Sherman
  • ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20190225664
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: September 4, 2018
    Publication date: July 25, 2019
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Methods for treating vascular eye disorders with actrii antagonists
    Patent number: 10301372
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 28, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • METHODS FOR TREATING FATTY LIVER DISEASE
    Publication number: 20190062392
    Abstract: In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
    Type: Application
    Filed: March 19, 2018
    Publication date: February 28, 2019
    Inventors: Alan Koncarevic, Jennifer Lachey, Jasbir Seehra, Matthew L. Sherman
  • Antagonists of activin-ActRIIa and uses for increasing red blood cell levels
    Patent number: 10093707
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: October 9, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • Follistatin fusion proteins and uses thereof
    Patent number: 9919030
    Abstract: In certain aspects, the present invention provides methods for dosing a patient with a follistatin antagonist and methods for managing patients treated with a follistatin antagonist.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: March 20, 2018
    Assignee: ACCELERON PHARMA INC.
    Inventor: Matthew L. Sherman
  • ANTAGONISTS OF ACTRIIB AND USES FOR INCREASING RED BLOOD CELL LEVELS
    Publication number: 20180009872
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: July 18, 2017
    Publication date: January 11, 2018
    Inventors: Matthew L. Sherman, Jasbir Seehra, Niels Borgstein
  • METHODS FOR TREATING EYE DISORDERS
    Publication number: 20170291935
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Application
    Filed: November 23, 2016
    Publication date: October 12, 2017
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • METHODS FOR TREATING FATTY LIVER DISEASE
    Publication number: 20160318983
    Abstract: In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 3, 2016
    Inventors: Alan Koncarevic, Jennifer Lachey, Jasbir Seehra, Matthew L. Sherman